News
-
Grifols Enters Into Global Collaboration And Licensing Agreement With Selagine To Develop Immunoglobulin Eye Drops To Treat Dry Eye Disease
3/6/2023
Grifols one of the world’s leading producers of plasma-derived medicines, today announced a global collaboration and licensing agreement with Selagine Inc, a company focused on developing novel therapeutics for ocular diseases, to treat dry eye disease (DED) with immunoglobulin eye drops.
-
eXmoor Pharma And Vaccine Developer Imophoron Sign Process Development Partnership
2/22/2023
eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and Imophoron, the developer of a novel, next generation thermostable vaccine platform, ADDomer, to combat present and future infectious diseases, today announce the signature of a strategic process development partnership that includes a future GMP manufacturing route.
-
CDMO Dalton Pharma Services Announces Major Expansion With New Filling And Lyophilization Technology
2/16/2023
Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology.
-
LIfT BioSciences And Minaris Regenerative Medicine Enter Into A Development And Manufacturing Partnership For N-LIfT Allogeneic Neutrophil Based Cell Therapy
2/16/2023
LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and manufacturing partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid tumours.
-
Windgap Medical Appoints Aaron Mann As CEO, Michael Samar As CFO
2/13/2023
Both bring significant industry tenure and experience to their roles, and with Windgap Co-Founder Brent Buchine, will lead the company's continued growth in the field of complex injectable drug delivery solutions.
-
Elektrofi Announces Collaboration With Thermo Fisher Scientific To Strengthen Manufacturing Capabilities For Future Clinical Trials
2/7/2023
Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, today announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.
-
Phillips-Medisize Expands Product Portfolio With Launch Of A Pen Injector Platform Designed To Lower Pharma Costs, Risks And Market Barriers
2/1/2023
Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, has expanded its product portfolio with the introduction of a disposable pen injector.
-
Lilly Plans To Invest Additional $450M At Manufacturing Site In Research Triangle Park
1/24/2023
Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly's incretin products that treat diabetes.
-
Stevanato Group Collaborates With Transcoject To Provide Pre-Fillable Syringe Polymer Options For Pharma
1/24/2023
Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its latest collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company.
-
Parenteral Drug Association Announces New EU GMP Annex 1 Implementation Interest Group
1/20/2023
PDA is pleased to announce the formation of the Annex 1 Implementation Interest Group, which will begin meeting in February.